VYGR Voyager Therapeutics, Inc.
2.470USD+0.41%Mkt Cap: 152.20M $P/E: —1d ago
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibod…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.27BUSDP/E 30.7
$22.99BUSDP/E 14.5
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +27.27% and -9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||